Teriparatide

Teriparatide is a recombinant analogue of the biologically active N-terminal 34 amino acids of human parathyroid hormone (PTH 1-34). It binds the PTH type 1 receptor (PTH1R), a G-protein-coupled receptor expressed on osteoblasts and osteocytes, activating adenylate cyclase and phospholipase C to elevate intracellular cyclic AMP and calcium.

The pharmacological key is intermittency. Continuous PTH exposure, as occurs in primary hyperparathyroidism, drives bone resorption via osteoclast activation. Once-daily subcutaneous injection creates a brief transient peak in serum PTH followed by rapid clearance, a pulsatile profile that selectively favors bone formation over resorption — the so-called anabolic window.

At the cellular level, intermittent PTH1R activation increases osteoblast number through three overlapping mechanisms: reduced apoptosis of existing osteoblasts, accelerated differentiation of osteoprogenitor lining cells, and suppression of sclerostin in osteocytes. Sclerostin suppression de-represses the Wnt/beta-catenin pathway, diverting mesenchymal stem cell differentiation toward osteoblastogenesis rather than adipogenesis. PTH also stimulates local production of insulin-like growth factor-1 (IGF-1) and fibroblast growth factor-2 (FGF2), amplifying the anabolic signal. The net result is preferential bone modeling on trabecular surfaces — occurring without requiring prior resorption — rapidly increasing bone volume, trabecular connectivity, and cortical thickness.

Teriparatide received FDA approval in November 2002, supported by a body of large randomized controlled trials.

The landmark Fracture Prevention Trial (Neer et al., N Engl J Med 2001; PMID 11346808; n=1,637 postmenopausal women with at least one prior vertebral fracture) is the pivotal study. After a median 21 months, teriparatide 20 mcg/day reduced new vertebral fractures by 65% (RR 0.35; 95% CI 0.22–0.55) and nonvertebral fragility fractures by 53% (RR 0.47; 95% CI 0.25–0.88) versus placebo. Lumbar spine BMD increased by approximately 9% and femoral neck BMD by approximately 3%.

The VERO trial (Kendler et al., Lancet 2018; PMID 29129436; n=1,360) was a two-year double-blind, double-dummy RCT comparing teriparatide 20 mcg/day versus risedronate 35 mg/week in women with severe established osteoporosis (at least two moderate or one severe prior vertebral fracture). New vertebral fractures occurred in 5.4% of the teriparatide group versus 12.0% in the risedronate group (RR 0.44; 95% CI 0.29–0.68; p<0.0001). Clinical fractures occurred in 4.8% versus 9.8% (HR 0.48; p=0.0009), representing the first head-to-head fracture-endpoint superiority demonstration against an active comparator.

In glucocorticoid-induced osteoporosis, an 18-month RCT by Saag et al. (N Engl J Med 2007; PMID 18003959; n=428 women and men on chronic glucocorticoids) showed teriparatide produced significantly greater lumbar spine and hip BMD gains than alendronate, with fewer new vertebral fractures.

A 2024 systematic review (PMC11026046) pooling multiple controlled trials confirmed approximately 67% reduction in vertebral fractures and 38% reduction in nonvertebral fractures versus placebo. Fifteen years of post-marketing surveillance across an estimated 2.47 million teriparatide-exposed patients formed the basis for FDA removal of the osteosarcoma boxed warning in 2020.

Typical dosage: 20 mcg (daily).

The FDA-approved dose is 20 mcg administered once daily by subcutaneous injection into the thigh or abdominal wall. The formulation is supplied as a 3 mL pre-filled multi-dose pen containing 750 mcg of teriparatide at a concentration of 250 mcg/mL; each pen delivers 28 daily doses at the approved dose.

Duration of use: original labeling capped total lifetime use at 2 years. A 2020 label update revised this to permit use beyond 2 years when the patient remains at or has returned to high fracture risk. Upon completing a teriparatide course, current clinical practice strongly favors immediate transition to an antiresorptive agent (bisphosphonate or denosumab) to preserve BMD gains, as bone density declines measurably within months of discontinuation without follow-on therapy.

Supplemental calcium (approximately 1,000–1,200 mg/day) and vitamin D (400–800 IU/day) are recommended throughout therapy if dietary intake is inadequate.

The first dose should be administered while seated or lying down, as transient orthostatic hypotension may occur within four hours of dosing.

A 40 mcg/day dose was explored in earlier trials and produced higher BMD gains but also greater hypercalcemia rates. This dose is not currently FDA-approved nor recommended in clinical practice.

This information is provided for educational and reference purposes only and does not constitute medical advice. Teriparatide is a prescription medication; dosing decisions must be individualized by a qualified healthcare provider.

Lyophilized (before reconstitution)

Refrigerate 2–8°C at all times, including during the in-use period. Do not freeze. Keep the pen in the original carton to protect from light.

Reconstituted

Forteo: inject immediately upon removal from the refrigerator and return the pen to the fridge right after use. A travel allowance permits temperatures up to 25°C for no more than 36 hours total across the pen's in-use life.

For general storage chemistry (bacteriostatic vs sterile water, freeze-thaw, BUD framework), see Storage & handling.

Last reviewed: July 1, 2026

The most clinically supported combination strategy is sequential therapy: teriparatide first as an anabolic agent, followed by an antiresorptive to consolidate gains. Evidence from multiple trials demonstrates that the anabolic-first sequence (teriparatide → bisphosphonate or denosumab) produces and preserves the largest BMD improvements. Reversing this sequence — initiating antiresorptives before teriparatide, particularly potent bisphosphonates such as alendronate — results in a blunted initial BMD response to teriparatide, though available data suggest this blunting does not significantly increase fracture risk.

The DATA trial (n=94) investigated concurrent teriparatide and denosumab. Combination therapy increased spine BMD by approximately 9% at 12 months versus approximately 6% with either monotherapy, and hip BMD by approximately 5% versus under 2%, with cortical porosity remaining stable in the combination arm. This is the best-documented synergistic combination under controlled trial conditions.

Concurrent teriparatide plus bisphosphonate is generally not recommended. Bisphosphonates restrict osteoclast activity and may blunt the anabolic response by reducing matrix remodeling required for new bone formation. The clinical guideline consensus supports completion of teriparatide followed by antiresorptive consolidation as the standard paradigm.

Teriparatide is approved by the U.S. Food and Drug Administration for one or more clinical indications. Refer to the prescribing information for full safety and dosing details.

PeptideSciences101 does not endorse vendors. For transparency metrics and third-party testing notes, see the vendor directory.

Reported side effects: Dizziness, leg cramps, nausea

Common adverse effects reported in controlled trials include nausea, headache, arthralgia, pain, asthenia, leg cramps, rhinitis, and dizziness. Injection-site reactions (pain, swelling, erythema, pruritus) are generally mild and transient.

Orthostatic hypotension occurs in approximately 5% of patients, typically within four hours of dosing. The prescribing label advises administering the first dose while seated or supine, with patients observed until symptoms, if any, resolve.

Transient hypercalcemia above the normal range has been reported in approximately 11% of women and 6% of men during therapy. It is generally mild and self-limited but warrants baseline and periodic serum calcium monitoring, particularly in patients with conditions predisposing to calcium dysregulation. Hypercalciuria and modest elevations in serum uric acid have also been reported.

The original FDA boxed warning regarding osteosarcoma risk — which arose from lifetime rodent toxicology studies showing dose-dependent osteosarcoma in rats — was removed in November 2020. Post-marketing surveillance spanning 15 years and approximately 2.47 million exposed patients identified 3 observed osteosarcoma cases against 4.17 expected (standardized incidence ratio 0.72), demonstrating no excess risk in humans. Mechanistic differences between rodent and human bone biology (continuous skeletal growth and absence of osteonal remodeling in rats) are considered the basis for the species-specific finding.

Absolute contraindications include hypersensitivity to teriparatide; conditions that increase baseline osteosarcoma risk (Paget's disease of bone, unexplained alkaline phosphatase elevation, open epiphyses in pediatric patients, prior radiation therapy involving the skeleton, or bone metastases); primary hyperparathyroidism; and pre-existing hypercalcemia. Caution is warranted in patients with impaired renal function or nephrolithiasis. Teriparatide is not approved for use in pediatric patients.